PGG glucan - Biothera

Drug Profile

PGG glucan - Biothera

Alternative Names: B-glucan PGG; BTH-1677; Imprime PGG; Soluble beta glucan - Biothera

Latest Information Update: 14 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biothera
  • Developer Biothera; Dana-Farber Cancer Institute; Mayo Clinic; Merck Sharp & Dohme
  • Class Antibacterials; Antineoplastics; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Breast cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Phase I/II Chronic lymphocytic leukaemia
  • Research Follicular lymphoma
  • Suspended Infections
  • No development reported Pancreatic cancer
  • Discontinued Myelosuppression; Stem cell mobilisation

Most Recent Events

  • 05 Sep 2018 Biothera enters into an agreement with AstraZeneca for a clinical evaluation in Head and neck cancer (Combination therapy, First-line therapy, Late-stage disease)
  • 05 Sep 2018 Biothera plans a phase II trial for Head and neck cancer (Combination therapy, First-line therapy, Late-stage disease) in USA
  • 29 Aug 2018 Roche initiates a phase I/II trial for Colorectal cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (NCT03555149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top